摘要
目的 :通过临床观察黄芪注射液防护顺铂致早期肾损害的疗效及其对顺铂抗肿瘤作用的影响。方法 :将试验组随机双盲分为 3组 :A组 (对照组 )单用顺铂联合化疗 ;B组 (研究组 )顺铂加黄芪注射液 1g/kg .日 ;C组 (研究组 )顺铂加黄芪注射液 2 g/kg .日。试验期为 4个周期 ,每周期 4周。 结果 :黄芪注液 2个剂量组的尿微量白蛋白 (UAE)、血和尿 β2 微球蛋白 (β2 -MG)、肌酐清除率 (Ccr)、血尿酸 (UA)等各项生化指标 ,无显著性差异 (P >0 .0 5 )。以上 2组的检测值明显低于单用顺铂联合化疗组 ,差异显著 (P <0 .0 5 )。。结论
Objective: To investigate the clinical effects of Astragalus Injection on preventing cisplatin induced early kidney injury and anti tumor of cisplatin. Methods: The subjects were divided into three groups at random.Group A(the contr group) was treated with cisplatin alone chemotheray. Group B (the study group) was treated with cisplatin and Astragalus Injection in a dosage of 1g/kg a day. Group C(the study group) was treated with cisplatin and Astragalus Injection in a dosage of 2g/kg a day. One test course included four periods, four weeks Per period. Results: The biochemical markers such as urinary microgalbumin(UAE),blood and urinary β 2 microglobulin (β -MG),creatinine clearance rate (Ccr) and blood uric acid (UA) in two dose groups of Astragalus Injection were similar. No remarkable difference were observed ( P >0.05). But the determined values in the above two dose groups of Astragalus Injection were obviously lower than that in cisplatin group. There were remarkable differences.( P <0.05). Conclusion: The different doses of Astragalus Injection can prevent the kidney injury induced by cisplatin and has no effect on anti tumor activity of cisplatin.
出处
《中成药》
CAS
CSCD
北大核心
2001年第4期265-267,共3页
Chinese Traditional Patent Medicine
